Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3970 - COnsensus statement on Mandatory Measurements in PAncreatic Cancer Trials for systemic treatment of unresectable disease (COMM-PACT)


09 Sep 2017


Poster display session


Pancreatic Cancer


L. Bengt van Rijssen


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


L..B. van Rijssen1, E. ter Veer2, M.G. Besselink1, R.M.A. Mali2, J. Berlin3, S. Boeck4, F. Bonnetain5, T. Conroy6, G. Deplanque7, D. Goldstein8, B. Glimelius9, J.P. Neoptolemos10, M. Reni11, W. Scheithauer12, J. van der Meer1, J.W. Wilmink2, M.J. van der Poel1, O.R. Busch1, M.G.H. van Oijen2, H.W.M. van Laarhoven2

Author affiliations

  • 1 Department Of Surgery, Academic Medical Center (AMC), 1105AZ - Amsterdam/NL
  • 2 Department Of Medical Oncology, Academic Medical Center (AMC), 1105AZ - Amsterdam/NL
  • 3 Medical Oncology, Vanderbilt Ingram Cancer Center, 37232-6307 - Nashville/US
  • 4 Department Of Internal Medicine Iii, Comprehensive Cancer Center, Ludwig-Maximilians-University of Munich, 81377 - Munich/DE
  • 5 Methodological And Quality Of Life Unit In Oncology (ea 3181), CHRU Besançon Jean Minjoz, 25000 - Besançon/FR
  • 6 Medical Oncology, Institut de Cancérologie de Lorraine, 54519 - Vandoeuvre-Lès-Nancy/FR
  • 7 Medical Oncology, Hopital Riviera Chablais, 1800 - Vevey/CH
  • 8 Cancer Survivors Centre, University of New South Wales Cancer Research Centre, 2052 - Sydney/AU
  • 9 Immunology, Genetics And Pathology, University Hospital, SE-751 85 - Uppsala/SE
  • 10 Surgical Oncology, University of Liverpool, Liverpool/GB
  • 11 Medical Oncology, IRCCS San Raffaele Scientific Institute, 20132 - Milan/IT
  • 12 Department Of Internal Medicine, Vienna General Hospital (AKH) - Medizinische Universität Wien, 1090 - Vienna/AT


Abstract 3970


Variations in the reporting of potentially confounding variables in studies investigating systemic treatments of unresectable pancreatic cancer challenge adequate comparisons. We establish the first international consensus on mandatory baseline- and prognostic characteristics to be taken into account in future pancreatic cancer trials for patients with unresectable disease.


A systematic review was performed for phase III trials investigating first-line systemic therapy for unresectable pancreatic cancer that were published between January 2000 and January 2016 to identify baseline characteristics and prognostic variables. The electronic databases Medline, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) were used. A structured overview was created demonstrating the reporting frequencies of baseline characteristics and prognostic relevance of identified variables. A modified Delphi panel of two rounds involving 23 leading medical-oncologists in the field of pancreatic cancer was used to develop the consensus.


A total of 624 studies were identified. After screening, 39 randomized controlled trials (RCTs) with 15,863 patients were included. Thirty-two baseline characteristics and 26 prognostic characteristics were identified. After two consensus rounds, 24 baseline characteristics and twelve prognostic characteristics were designated as a mandatory reporting set for future trials. Table 1. Mandatory setTable:


Baseline characteristicsPrognostic characteristics
Biliary stentBilirubin
BilirubinCA 19.9
C-Reactive Protein (CRP)Disease status
Disease statusLDH
GenderLiver metastasis
LDHNumber of metastatic sites
Liver metastasisPain at baseline
Loss of weight > 10%Performance status
Neutrophil lymphocyte ratio (NLR)
Number of metastatic sites
Pain at baseline
Performance status
Peritoneal metastasis
Primary tumor location
Prior chemotherapy/radiotherapy
Prior surgery
Pulmonary metastasis
Time from diagnosis
Tumor differentiation


The COnsensus statement on Mandatory Measurements identifies a set of baseline- and prognostic characteristics in unresectable PAncreatic Cancer Trials (COMM-PACT) that allows for adequate comparison of outcomes between studies.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Not applicable




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.